Table 4 Patients receiving single pharmacologic therapy.

From: Response of the ductus arteriosus to acetaminophen or indomethacin in extremely low birth weight infants

 

Acetaminophen (n = 58)

Indomethacin (n = 16)

p value

GA at birth, weeks (median, IQR)

25 [24–26]

26 [24–27]

0.37

Birth weight, grams (median, IQR)

685 [600–877]

808 [648–872]

0.36

Female

35 (60%)

10 (62%)

0.88

Cesarean delivery

48 (83%)

14 (88%)

0.65

IUGR Present

16 (28%)

5 (31%)

0.77

Inborn delivery

38 (66%)

15 (94%)

0.027

Race

 African American

19 (33%)

4 (25%)

0.21

 African American/White

2 (3%)

0 (0%)

 Asian

0 (0%)

1 (6%)

 Asian/White

2 (3%)

0 (0%)

 Hispanic/Latino

1 (2%)

1 (6%)

 Unknown

5 (9%)

0 (0%)

 White

29 (50%)

10 (62%)

Apgar score

 1 min

2.0 [1.0–4.0]

4.5 [3.0–6.0]

0.004

 5 min

6.0 [4.0–7.8]

7.0 [6.0–8.0]

0.028

 10 min

7.0 [6.0–8.0]

7.0 [7.0–7.0]

0.92

Received indomethacin prophylaxis

34 (59%)

10 (62%)

0.78

Vasopressor requirementa,b, n

8 (12%)

3 (17%)

0.61

 VISMAX

5.5 [5.0–10.0]

5.0 [5.0–6.0]

---

Respiratory support typea,b, n

  

---

 Mechanical ventilation

44

8

 

 CPAP

20

10

 

 High flow nasal cannula

2

0

 

RSSMVa,b,c

3.5 [2.9–5.2]

4.3 [3.5–5.3]

0.53

RSSCPAPa,b,d

1.4 [1.1–1.5]

1.4 [1.2–1.5]

0.86

Age at therapy start, daysa,b (median, IQR)

13.5 [9.0–19.0]

9.0 [5.2–15.0]

0.022

Age < 14 days at starta,b

33 (50%)

12 (67%)

0.21

Toxicityb,e

8 (12%)

1 (6%)

0.42

Successful PDA closureb

14 (21%)

5 (28%)

0.56

Surgical closure

21 (36%)

2 (11.5%)

0.069

  1. aOn day of PDA therapy start.
  2. bData presented by course: 66 acetaminophen courses, 18 indomethacin courses.
  3. cRSSMV = (median FiO2 x median MAP)/100.
  4. dRSSCPAP = (median PEEP x median FiO2)/100.
  5. eToxicity in acetaminophen group defined as elevated AST or ALT; toxicity in indomethacin group defined as suspected acute kidney injury or thrombocytopenia requiring a change in therapy.
Back to article page